Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Corline Biomedical

17.55 SEK

-1.13 %

Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.13 %
-9.77 %
+17.00 %
+80.93 %
+99.89 %
+137.80 %
+84.35 %
+25.33 %
+77.42 %

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
449.52M SEK
Turnover
7.38K SEK
Revenue
9.78M
EBIT %
-236.91 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.2
2026

Annual report '25

8.5
2026

Interim report Q1'26

26.8
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Press release11/19/2025, 7:25 AM

Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming

Corline Biomedical
Press release9/2/2025, 8:29 AM

Redeye: Corline Biomedical - Kardium receives FDA approval

Corline Biomedical
Press release8/27/2025, 9:54 AM

Redeye: Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/11/2025, 3:51 PM

Redeye: Corline Biomedical Q1 - Exciting quarters ahead

Corline Biomedical
Press release2/18/2025, 7:34 AM

Redeye: Corline Biomedical Q4 - Focus on Kardium’s market launch

Corline Biomedical
Press release2/4/2025, 6:47 AM

Redeye: Redeye Initiates Coverage of Corline Biomedical

Corline Biomedical
Regulatory press release5/16/2019, 4:09 PM

Corline Biomedical AB: Will present at investor event hosted by Aktiespararna on June 3rd in Stockholm

Corline Biomedical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.